menu
    • menu
    [{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Miragen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Sciences \/ Miragen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Miragen Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Viridian Sciences

    Menu

    Viridian Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Viridian Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Viridian Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R Antibody for The Tr...

                            Details : VRDN-001, Viridian’s lead TED program, is an intravenously administered anti-IGF-1R monoclonal antibody. This antibody was previously in development as AVE1642 and was studied in more than 100 oncology patients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 14, 2021

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viridian Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Viridian Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Miragen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc

                            Details : miRagen gains Viridian's clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, a clinical-stage insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) to treat thyroid eye disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 28, 2020

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Miragen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth